BELLUS Health is a clinical stage biotechnology company focused on developing a P2X3 antagonist to address chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of chronic cough.